Vivozon Healthcare Inc
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications. It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as w… Read more
Vivozon Healthcare Inc (082800) - Net Assets
Latest net assets as of September 2025: ₩87.70 Billion KRW
Based on the latest financial reports, Vivozon Healthcare Inc (082800) has net assets worth ₩87.70 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩170.43 Billion) and total liabilities (₩82.73 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩87.70 Billion |
| % of Total Assets | 51.46% |
| Annual Growth Rate | 5.27% |
| 5-Year Change | -1.28% |
| 10-Year Change | 331.68% |
| Growth Volatility | 94.13 |
Vivozon Healthcare Inc - Net Assets Trend (2009–2024)
This chart illustrates how Vivozon Healthcare Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vivozon Healthcare Inc (2009–2024)
The table below shows the annual net assets of Vivozon Healthcare Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩106.43 Billion | +2.27% |
| 2023-12-31 | ₩104.07 Billion | -1.67% |
| 2022-12-31 | ₩105.84 Billion | +24.34% |
| 2021-12-31 | ₩85.12 Billion | -21.04% |
| 2020-12-31 | ₩107.80 Billion | -1.10% |
| 2019-12-31 | ₩109.00 Billion | +59.24% |
| 2018-12-31 | ₩68.45 Billion | +325.14% |
| 2017-12-31 | ₩16.10 Billion | -29.21% |
| 2016-12-31 | ₩22.74 Billion | -7.75% |
| 2015-12-31 | ₩24.65 Billion | -27.27% |
| 2014-12-31 | ₩33.90 Billion | -39.63% |
| 2010-12-31 | ₩56.15 Billion | +14.05% |
| 2009-12-31 | ₩49.23 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vivozon Healthcare Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 99429.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩378.26 Billion | 355.41% |
| Total Equity | ₩106.43 Billion | 100.00% |
Vivozon Healthcare Inc Competitors by Market Cap
The table below lists competitors of Vivozon Healthcare Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Peace Bird Fashion
SHG:603877
|
$139.78 Million |
|
Fennec Pharmaceuticals Inc
NASDAQ:FENC
|
$139.80 Million |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
$139.82 Million |
|
Prince Pipes And Fittings Limited
NSE:PRINCEPIPE
|
$139.83 Million |
|
Southeast Cement Co Ltd
TW:1110
|
$139.76 Million |
|
Seetel New Energy Co., Ltd.
TW:7740
|
$139.72 Million |
|
ELEDON PHARMACEUT.DL-001
F:2TK
|
$139.71 Million |
|
Fireweed Zinc Ltd
OTCQX:FWEDF
|
$139.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivozon Healthcare Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 104,067,052,070 to 106,426,761,450, a change of 2,359,709,380 (2.3%).
- Net loss of 9,982,009,310 reduced equity.
- Other factors increased equity by 12,341,718,690.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-9.98 Billion | -9.38% |
| Other Changes | ₩12.34 Billion | +11.6% |
| Total Change | ₩- | 2.27% |
Book Value vs Market Value Analysis
This analysis compares Vivozon Healthcare Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.65x to 1.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩599.47 | ₩3385.00 | x |
| 2017-12-31 | ₩424.37 | ₩3385.00 | x |
| 2018-12-31 | ₩919.23 | ₩3385.00 | x |
| 2019-12-31 | ₩905.06 | ₩3385.00 | x |
| 2020-12-31 | ₩766.46 | ₩3385.00 | x |
| 2021-12-31 | ₩2504.91 | ₩3385.00 | x |
| 2022-12-31 | ₩2261.07 | ₩3385.00 | x |
| 2023-12-31 | ₩2158.54 | ₩3385.00 | x |
| 2024-12-31 | ₩2045.64 | ₩3385.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivozon Healthcare Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.39%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.73x
- Recent ROE (-9.38%) is above the historical average (-27.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -3.83% | -1.08% | 2.24x | 1.58x | ₩-4.69 Billion |
| 2015 | -39.34% | -10.81% | 1.84x | 1.98x | ₩-12.16 Billion |
| 2016 | -7.83% | -2.61% | 1.63x | 1.85x | ₩-4.06 Billion |
| 2017 | -41.42% | -10.93% | 1.68x | 2.26x | ₩-8.28 Billion |
| 2018 | -12.47% | -18.55% | 0.46x | 1.47x | ₩-15.38 Billion |
| 2019 | -25.69% | -62.28% | 0.27x | 1.51x | ₩-38.90 Billion |
| 2020 | -40.59% | -100.37% | 0.18x | 2.30x | ₩-54.53 Billion |
| 2021 | -81.60% | -120.31% | 0.30x | 2.28x | ₩-77.97 Billion |
| 2022 | -37.70% | -77.39% | 0.28x | 1.77x | ₩-50.49 Billion |
| 2023 | -3.23% | -4.71% | 0.41x | 1.67x | ₩-13.76 Billion |
| 2024 | -9.38% | -11.39% | 0.47x | 1.73x | ₩-20.62 Billion |
Industry Comparison
This section compares Vivozon Healthcare Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivozon Healthcare Inc (082800) | ₩87.70 Billion | -3.83% | 0.94x | $139.77 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |